Adverse Effects Reduce Drug Efficacy in OCD
Feb 9, 2016
A study of treatment tolerance and therapeutic response in children and adolescents with OCD.
Kenneth J. Bender, PharmD, MA
New Analysis of Antidepressants in Pregnancy Finds Little Added Risk of Newborn Pulmonary Hypertension
Jul 30, 2015
An overview of the largest study to examine persistent pulmonary hypertension in newborns (PPHN) exposed to antidepressants late in pregnancy.
Large Trials for First-Episode Psychosis: One Debuts, Another Marks 10 Years
May 19, 2015
Progress in identifying and effectively treating first-episode schizophrenia was marked by the simultaneous publication of a report on a 6-year study and on the 10-year follow-up of a large-scale trial.
Olanzapine/Fluoxetine Combination Affirmed for Bipolar Depression
Jul 17, 2013
A recent meta-analysis supports evidence of the effectiveness of the fixed olanzapine/fluoxetine combination (Symbyax) in treating the depressive phase of bipolar disorder. Response was ranked higher, but with no more adverse effects, than with treatment with olanzapine alone.
“PRN” Medication for Alcohol Dependence May Reduce Harm
Jun 18, 2013
In a new study, "as needed" use of an opioid antagonist for heightened alcohol craving appeared to reduce the number of heavy drinking days and total amount of alcohol consumed.
No Mortality Increase With Antipsychotics in Prospective Study
Jun 17, 2013
Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.
Irreversible Monoamine Oxidase Inhibitors Revisited
Oct 8, 2012
Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.
FDA Panel Votes to Curtail Cranial Electrotherapy Stimulators
Jul 14, 2012
The FDA Neurological Devices Panel met to consider the Agency’s proposal to reclassify cranial electrotherapy stimulator (CES) devices to Class III with premarket approval.
Refeeding Regimens for Anorexia Challenged
Feb 9, 2012
A new study examining conventional “start low, go slow” nutrition replenishment protocols for hospitalized patients with anorexia nervosa (AN) that have been recommended by professional organizations and it's outcomes.
Mixed Evidence for Omega-3 Supplementation for Major Depressive Disorder
Oct 8, 2011
A meta-analysis of the Omega-3 fatty acid EPA (eicosapentaenoic acid) as therapeutic supplement for major depression followed the above study online September 6 in the Journal of Clinical Psychiatry.
